INCIDENCE OF THROMBOTIC EVENTS IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA AND ITS INFLUENCE ON THE OUTCOME OF THESE PATIENTS: EXPERIENCE OF SINGLE CENTER
(Abstract release date: 05/21/15)
EHA Library. Hidalgo Lopez J. 06/12/15; 102680; PB1666
Disclosure(s): University Hospital Vall d’HebronHematology
Juliana Hidalgo Lopez
Contributions
Contributions
Abstract
Abstract: PB1666
Type: Publication Only
Background
Primary Mediastinal B cell Lymphoma (PMBL) is a lymphoid neoplasm that accounts for 2 to 4% of non-Hodgkin lymphomas (NHL). Because of its particular features (fibrosis, large mediastinal mass, pericardial and/or pleural effusion) is included in the Large B-cell lymphomas (LBCL) with special features category. PMBL presents usually with superior vena cava syndrome (SVCS) and thrombotic events of the mediastinal circulation although the real prevalence of these events have not been accurately reported in the literature.
Aims
The main objective of the study was to determine the incidence of these thrombotic events and how this complication influences the outcome of patients diagnosed with PMBL.
Methods
Thirty-one patients consecutively diagnosed with PMBL in a single center between 1995 and 2014 were included. After reviewing the pathology, the demographic and clinical characteristics of the series were recorded and evaluated, paying particular attention to the thrombotic events.
Results
The median age at diagnosis was 34 years (range: 17 to 56) and 61% were female. The median of the largest diameter of the mediastinal mass was 98 mm (range: 50-150 mm), 26% had extranodal involvement (most frequently associated with adjacent structures) and 52% had SVCS. Ten patients (32%) had thrombotic events, 90% detected at diagnosis. There were no differences between the clinical characteristics (sex, age, larger diameter of the mediastinal mass, SVCS presence or extranodal involvement) between patients with or without thrombotic events. With a median follow-up of 71 months (range: 1-183) we did not find any difference between patients with or without thrombotic events regarding the response to therapy and the outcome (PFS and OS), Table 1.
Summary
The prevalence of thrombotic events in PMBL reported in our study is higher than the one described in other types of lymphomas. Nevertheless, response to therapy and outcome seems not to be influenced by this complication.
Keyword(s): B cell lymphoma, Non-Hodgkin's lymphoma, Thrombosis
Session topic: Publication Only
Type: Publication Only
Background
Primary Mediastinal B cell Lymphoma (PMBL) is a lymphoid neoplasm that accounts for 2 to 4% of non-Hodgkin lymphomas (NHL). Because of its particular features (fibrosis, large mediastinal mass, pericardial and/or pleural effusion) is included in the Large B-cell lymphomas (LBCL) with special features category. PMBL presents usually with superior vena cava syndrome (SVCS) and thrombotic events of the mediastinal circulation although the real prevalence of these events have not been accurately reported in the literature.
Aims
The main objective of the study was to determine the incidence of these thrombotic events and how this complication influences the outcome of patients diagnosed with PMBL.
Methods
Thirty-one patients consecutively diagnosed with PMBL in a single center between 1995 and 2014 were included. After reviewing the pathology, the demographic and clinical characteristics of the series were recorded and evaluated, paying particular attention to the thrombotic events.
Results
The median age at diagnosis was 34 years (range: 17 to 56) and 61% were female. The median of the largest diameter of the mediastinal mass was 98 mm (range: 50-150 mm), 26% had extranodal involvement (most frequently associated with adjacent structures) and 52% had SVCS. Ten patients (32%) had thrombotic events, 90% detected at diagnosis. There were no differences between the clinical characteristics (sex, age, larger diameter of the mediastinal mass, SVCS presence or extranodal involvement) between patients with or without thrombotic events. With a median follow-up of 71 months (range: 1-183) we did not find any difference between patients with or without thrombotic events regarding the response to therapy and the outcome (PFS and OS), Table 1.
Summary
The prevalence of thrombotic events in PMBL reported in our study is higher than the one described in other types of lymphomas. Nevertheless, response to therapy and outcome seems not to be influenced by this complication.
Keyword(s): B cell lymphoma, Non-Hodgkin's lymphoma, Thrombosis
Session topic: Publication Only
Abstract: PB1666
Type: Publication Only
Background
Primary Mediastinal B cell Lymphoma (PMBL) is a lymphoid neoplasm that accounts for 2 to 4% of non-Hodgkin lymphomas (NHL). Because of its particular features (fibrosis, large mediastinal mass, pericardial and/or pleural effusion) is included in the Large B-cell lymphomas (LBCL) with special features category. PMBL presents usually with superior vena cava syndrome (SVCS) and thrombotic events of the mediastinal circulation although the real prevalence of these events have not been accurately reported in the literature.
Aims
The main objective of the study was to determine the incidence of these thrombotic events and how this complication influences the outcome of patients diagnosed with PMBL.
Methods
Thirty-one patients consecutively diagnosed with PMBL in a single center between 1995 and 2014 were included. After reviewing the pathology, the demographic and clinical characteristics of the series were recorded and evaluated, paying particular attention to the thrombotic events.
Results
The median age at diagnosis was 34 years (range: 17 to 56) and 61% were female. The median of the largest diameter of the mediastinal mass was 98 mm (range: 50-150 mm), 26% had extranodal involvement (most frequently associated with adjacent structures) and 52% had SVCS. Ten patients (32%) had thrombotic events, 90% detected at diagnosis. There were no differences between the clinical characteristics (sex, age, larger diameter of the mediastinal mass, SVCS presence or extranodal involvement) between patients with or without thrombotic events. With a median follow-up of 71 months (range: 1-183) we did not find any difference between patients with or without thrombotic events regarding the response to therapy and the outcome (PFS and OS), Table 1.
Summary
The prevalence of thrombotic events in PMBL reported in our study is higher than the one described in other types of lymphomas. Nevertheless, response to therapy and outcome seems not to be influenced by this complication.
Keyword(s): B cell lymphoma, Non-Hodgkin's lymphoma, Thrombosis
Session topic: Publication Only
Type: Publication Only
Background
Primary Mediastinal B cell Lymphoma (PMBL) is a lymphoid neoplasm that accounts for 2 to 4% of non-Hodgkin lymphomas (NHL). Because of its particular features (fibrosis, large mediastinal mass, pericardial and/or pleural effusion) is included in the Large B-cell lymphomas (LBCL) with special features category. PMBL presents usually with superior vena cava syndrome (SVCS) and thrombotic events of the mediastinal circulation although the real prevalence of these events have not been accurately reported in the literature.
Aims
The main objective of the study was to determine the incidence of these thrombotic events and how this complication influences the outcome of patients diagnosed with PMBL.
Methods
Thirty-one patients consecutively diagnosed with PMBL in a single center between 1995 and 2014 were included. After reviewing the pathology, the demographic and clinical characteristics of the series were recorded and evaluated, paying particular attention to the thrombotic events.
Results
The median age at diagnosis was 34 years (range: 17 to 56) and 61% were female. The median of the largest diameter of the mediastinal mass was 98 mm (range: 50-150 mm), 26% had extranodal involvement (most frequently associated with adjacent structures) and 52% had SVCS. Ten patients (32%) had thrombotic events, 90% detected at diagnosis. There were no differences between the clinical characteristics (sex, age, larger diameter of the mediastinal mass, SVCS presence or extranodal involvement) between patients with or without thrombotic events. With a median follow-up of 71 months (range: 1-183) we did not find any difference between patients with or without thrombotic events regarding the response to therapy and the outcome (PFS and OS), Table 1.
Summary
The prevalence of thrombotic events in PMBL reported in our study is higher than the one described in other types of lymphomas. Nevertheless, response to therapy and outcome seems not to be influenced by this complication.
Keyword(s): B cell lymphoma, Non-Hodgkin's lymphoma, Thrombosis
Session topic: Publication Only
{{ help_message }}
{{filter}}